Do not administer by the intra-carotid route.

Careful consideration should also be given before administrating to animals exposed to stress conditions such as extreme heat, cold, high altitude or fatigue.

Following the use of Xylacare 2% in cattle, profuse salivation, bloat and polyuria may occur. Tympany should be avoided in recumbent cattle by maintaining the animal in sternal recumbency. Provision should also be made for facilitating dependent drainage from the mouth to avoid inhalation asphyxia.

Side effects such as bradycardia, cardiac arrhythmia and polyuria may occur in the horse. Following intravenous administration to horses a transient rise followed by a fall in blood pressure usually occurs. Vomiting is commonly observed in dogs and cats following use of the product. Xylacare 2% should not be administered during the later stages of pregnancy because of the risk of inducing premature parturition. As the safety of xylazine use during organogenesis has not been fully demonstrated by current methods it should be used with caution during the first month of pregnancy.

Animals must not be slaughtered for human consumption during treatment. Cattle may be slaughtered for human consumption only after 14 days from the last treatment. Not for use in animals from which milk is produced for human consumption. Not to be used in horses intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation.

Xylazine is an alpha adrenoceptor agonist acting primarily on alpha-2 receptors. Precautions should be taken to avoid accidental injection/self injection. Wash splashes from skin and eyes immediately.

In the event of accidental injection/self injection, seek urgent medical advice and show label and other product literature. DO NOT DRIVE as sedation and changes in blood pressure may occur.

Xylazine is an alpha adrenoceptor agonist whose toxicity may cause clinical effects including sedation, respiratory depression and coma, bradycardia and hypotension and hyperglycaemia. Ventricular arrhythmias have also been reported. Treatment should be supportive with appropriate intensive therapy.

Keep out of the reach of children.

For animal treatment only.